Brought to you by 
Elan to spin off Athena Diagnostics with IPO
24 Jun 2020
Executive Summary
Elan will spin off its Athena Diagnostics (tests for neurological disorders) subsidiary with an initial public offering to raise up to $120mm.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
Laboratory Testing Services
- Esoteric Laboratories
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Withdrawn
Deal Type
-
Financing
- IPO
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elan to spin off Athena Diagnostics with IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice